Develops and manufactures generic pharmaceutical products. Markets and sells branded pharmaceutical products. Now — the numbers.
This is an established company with proven profits.
Average growth of 7% a year over the last 4 years. Every year shown ended in profit.
The gap is $1.3B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 10.7× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades 41% below its peak. The market has trimmed its expectations for the company.
It pays out $1.72 per share each year — regular cash for whoever holds the stock.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 3/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.